Satralizumab
Satralizumab is a humanized monoclonal antibody that is used for the treatment of neuromyelitis optica spectrum disorders (NMOSD). It is marketed under the brand name Enspryng and is developed by Roche.
Mechanism of Action[edit | edit source]
Satralizumab works by binding to the interleukin-6 (IL-6) receptor and inhibiting the signal transduction of IL-6, a cytokine that plays a key role in the inflammatory process in NMOSD.
Clinical Trials[edit | edit source]
In clinical trials, Satralizumab has shown to reduce the risk of NMOSD relapse. Side effects were similar to those seen in the general population, with the most common being nasopharyngitis and headache.
Approval[edit | edit source]
Satralizumab was approved for medical use in the United States in August 2020. In the European Union, it was granted a conditional marketing authorization in April 2021.
See Also[edit | edit source]
Satralizumab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD